These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
55 related articles for article (PubMed ID: 320485)
21. Inhibition of adenosine deaminase by deaza derivatives of adenosine and purine riboside. Lupidi G; Riva F; Cristalli G; Grifantini M Ital J Biochem; 1982; 31(6):396-403. PubMed ID: 7184903 [TBL] [Abstract][Full Text] [Related]
22. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts. Holland MJ Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439 [TBL] [Abstract][Full Text] [Related]
23. Antiproliferative effects of 9-beta-D-arabinofuranosyladenine 5'-monophosphate and related compounds in combination with adenosine deaminase inhibitors against mouse leukemia L1210/C2 cells in culture. Cass CE; Tan TH; Selner M Cancer Res; 1979 May; 39(5):1563-9. PubMed ID: 85484 [TBL] [Abstract][Full Text] [Related]
24. Effects of substituted 1,2,3-triazoles on adenosine deaminase, guanine deaminase and xanthine oxidase. Lucacchini A; Segnini D; Da Settimo A; Livi O Ital J Biochem; 1979; 28(3):194-206. PubMed ID: 583599 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic effects of 9-beta-D-arabinofuranosyladenine and 2'-deoxycoformycin combinations on intracerebral leukemia. Lee SH; Caron N; Kimball AP Cancer Res; 1977 Jul; 37(7 Pt 1):1953-5. PubMed ID: 861931 [TBL] [Abstract][Full Text] [Related]
26. Recovery of 2'-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo. Agarwal RP Cancer Res; 1979 Apr; 39(4):1425-7. PubMed ID: 421226 [TBL] [Abstract][Full Text] [Related]
27. Inhibition by 2- or/and 8-substituted adenosine derivatives of adenosine deaminase and calmodulin-dependent phosphodiesterase. Sasaki Y; Ono Y Nucleic Acids Symp Ser; 1980; (8):s163-6. PubMed ID: 6265879 [TBL] [Abstract][Full Text] [Related]
28. Trazodone, a nontricyclic antidepressant, is an inhibitor of adenosine deaminase. Sheid B Res Commun Chem Pathol Pharmacol; 1985 Jan; 47(1):149-52. PubMed ID: 3983468 [TBL] [Abstract][Full Text] [Related]
29. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine. Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187 [No Abstract] [Full Text] [Related]
31. Increased toxicity of 9-beta-D-arabinofuranosyladenine in the presence of an inhibitor of adenosine deaminase. Plunkett W; Cohen SS Ann N Y Acad Sci; 1977 Mar; 284():91-102. PubMed ID: 280161 [No Abstract] [Full Text] [Related]
33. Effect of an adenosine deaminase inhibitor on survival of mouse pancreatic islet allografts. Lum CT; Sutherland DE; Eckhardt J; Matas AJ; Najarian JS Transplantation; 1979 May; 27(5):355-7. PubMed ID: 107635 [No Abstract] [Full Text] [Related]
34. Inhibitors of adenosine deaminase and the development of antiviral agents. Cohen SS Ann N Y Acad Sci; 1985; 451():204-14. PubMed ID: 2416257 [No Abstract] [Full Text] [Related]
35. Toxicities of adenosine and 2'-deoxyadrenosine in L cells treated with inhibitors of adenosine deaminase. Lapi L; Cohen SS Biochem Pharmacol; 1977 Jan; 26(1):71-6. PubMed ID: 299815 [No Abstract] [Full Text] [Related]
36. Adenosine deaminase inhibitors. Conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenines. Bastian G; Bessodes M; Panzica RP; Abushanab E; Chen SF; Stoeckler JD; Parks RE J Med Chem; 1981 Dec; 24(12):1383-5. PubMed ID: 7310814 [No Abstract] [Full Text] [Related]
37. Adenosine deaminase inhibitors: their role in chemotherapy and immunosuppression. Glazer RI Cancer Chemother Pharmacol; 1980; 4(4):227-35. PubMed ID: 7002342 [No Abstract] [Full Text] [Related]
38. Animal model for immune dysfunction associated with adenosine deaminase deficiency. Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908 [TBL] [Abstract][Full Text] [Related]
39. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors. Kefford RF; Fox RM Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985 [No Abstract] [Full Text] [Related]